|
KMID : 1154920220170010060
|
|
Korean Journal of Insurance Medicine
2022 Volume.17 No. 1 p.60 ~ p.75
|
|
|
|
|
Yeo Jin-Seok
Oh Jin-Young
|
|
|
Abstract
|
|
|
Background: Pain is a common symptom in pancreatic cancer patients, and proper pain control in managing pancreatic cancer patients is vital for the patient’s quality of life. Pain management in pancreatic cancer patients is mainly through strong opioids, and various interventional procedures are used for better pain management and reducing opioid requirements. In this study, we tried to investigate the actual pain control condition of pancreatic cancer patients in South Korea using the big data set provided by the Health Insurance Review and Assessment Service.
Methods: Evaluation of claims from 2009 to 2020 with the diagnosis of pancreatic cancer (ICD-10 code: C25) was conducted based on Korean healthcare in-hospital claims. After categorizing the claim data by year, the annual numbers of claims were analyzed. The numbers of opioid prescriptions and interventional treatment claims were calculated by summation by year. For the opioids, we also analyzed morphine equivalent dose (MED) per each claim and sub-analyzed by types. Finally, we observed the trends of year-by-year change in each procedure by the graphs and calculated compounded annual growth rate of the claims of opioid prescriptions and each procedure.
Results: There was 6,952,603 claims/year in patients with pancreatic cancer. The number of claims for pain management showed a steady increase year by year. The rate of claims for pain management out of total claims also continued to increase. Since 2016, the number of claims for pain management has been growing at a higher rate than before. Opioid prescriptions accounted for most of the claims for pain management. With the increase in the cases of opioid prescriptions, the prescription dose for opioids also increased. Oxycodone was the most prescribed opioid, followed by morphine and fentanyl. The number of interventional treatments also increased over the years.
Conclusion: Claims for pain management in patients with pancreatic cancer are increasing, most of which are opioid prescriptions. Claims of opioids and interventional treatments have seen a higher rate of increase in claims since 2016. Our results provide primary data for future research directions for effective pain treatment for pancreatic cancer patients.
|
|
|
KEYWORD
|
|
|
Pancreatic cancer, Pain management, Opioids, MED, Interventional treatments, South Korea
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|